Five of the eight NSCLC/lung cancers harboring a RASGRF fusion were adenocarcinomas (corresponding to the NSCLCs containing PACSIN2-RASGRF1, DLG1-RASGRF1, RP2-RASGRF1, NPTN-RASGRF1, and OCLN–RASGRF2; Supplementary Fig. 2). Here, RP2 is linked to lung cancer.